PT Kalbe Farma Tbk
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more
PT Kalbe Farma Tbk (PTKFF) - Total Assets
Latest total assets as of September 2025: $29.95 Trillion USD
Based on the latest financial reports, PT Kalbe Farma Tbk (PTKFF) holds total assets worth $29.95 Trillion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PT Kalbe Farma Tbk - Total Assets Trend (2005–2024)
This chart illustrates how PT Kalbe Farma Tbk’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PT Kalbe Farma Tbk - Asset Composition Analysis
Current Asset Composition (December 2024)
PT Kalbe Farma Tbk's total assets of $29.95 Trillion consist of 58.4% current assets and 41.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.1% |
| Accounts Receivable | $5.01 Trillion | 17.0% |
| Inventory | $6.50 Trillion | 22.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.74 Trillion | 5.9% |
| Goodwill | $615.45 Billion | 2.1% |
Asset Composition Trend (2005–2024)
This chart illustrates how PT Kalbe Farma Tbk's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PT Kalbe Farma Tbk's current assets represent 58.4% of total assets in 2024, a decrease from 76.8% in 2005.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, down from 19.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 1.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 22.1% of total assets.
PT Kalbe Farma Tbk Competitors by Total Assets
Key competitors of PT Kalbe Farma Tbk based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥774.73 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩331.46 Billion |
PT Kalbe Farma Tbk - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - PT Kalbe Farma Tbk generates 1.11x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, PT Kalbe Farma Tbk generates $ 11.01 in net profit.
PT Kalbe Farma Tbk - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.85 | 4.15 | 4.12 |
| Quick Ratio | 2.32 | 2.52 | 2.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $13.25 Trillion | $ 12.93 Trillion | $ 9.90 Trillion |
PT Kalbe Farma Tbk - Advanced Valuation Insights
This section examines the relationship between PT Kalbe Farma Tbk's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.37 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | $29.43 Trillion |
| Market Capitalization | $1.36 Billion USD |
Valuation Analysis
Below Book Valuation: The market values PT Kalbe Farma Tbk's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: PT Kalbe Farma Tbk's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for PT Kalbe Farma Tbk (2005–2024)
The table below shows the annual total assets of PT Kalbe Farma Tbk from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $29.43 Trillion | +8.77% |
| 2023-12-31 | $27.06 Trillion | -0.67% |
| 2022-12-31 | $27.24 Trillion | +6.14% |
| 2021-12-31 | $25.67 Trillion | +13.75% |
| 2020-12-31 | $22.56 Trillion | +11.35% |
| 2019-12-31 | $20.26 Trillion | +11.67% |
| 2018-12-31 | $18.15 Trillion | +9.21% |
| 2017-12-31 | $16.62 Trillion | +9.13% |
| 2016-12-31 | $15.23 Trillion | +11.17% |
| 2015-12-31 | $13.70 Trillion | +10.23% |
| 2014-12-31 | $12.43 Trillion | +9.81% |
| 2013-12-31 | $11.32 Trillion | +20.14% |
| 2012-12-31 | $9.42 Trillion | +13.82% |
| 2011-12-31 | $8.27 Trillion | +17.66% |
| 2010-12-31 | $7.03 Trillion | +8.49% |
| 2009-12-31 | $6.48 Trillion | +13.65% |
| 2008-12-31 | $5.70 Trillion | +11.01% |
| 2007-12-31 | $5.14 Trillion | +11.11% |
| 2006-12-31 | $4.62 Trillion | -0.19% |
| 2005-12-31 | $4.63 Trillion | -- |